Considerations for Clinical Trials Targeting the Myocardial Interstitium | Zendy

Gavin A. Lewis | Zendy; Susanna Dodd | Zendy; Josephine H. Naish | Zendy; Joseph B. Selvanayagam | Zendy; Marc R. Dweck | Zendy; Chris Miller | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Considerations for Clinical Trials Targeting the Myocardial Interstitium

Author(s) -

Gavin A. Lewis,

Susanna Dodd,

Josephine H. Naish,

Joseph B. Selvanayagam,

Marc R. Dweck,

Chris Miller

Publication year - 2019

Publication title -

jacc. cardiovascular imaging

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.79

H-Index - 120

eISSN - 1936-878X

pISSN - 1876-7591

DOI - 10.1016/j.jcmg.2019.03.034

Subject(s) - clinical trial , medicine , intensive care medicine , psychological intervention , risk stratification , pathology , psychiatry

The myocardial interstitium has emerged as a potential therapeutic target and as a biological entity to improve risk stratification and better guide existing interventions. Clinical trials focusing on the myocardial interstitium are required to establish causality and improve patient outcomes. This review will discuss issues around clinical trials targeting the myocardial interstitium, including antifibrotic therapies, efficacy outcome measurements, mechanistic outcome measurements and mediation analysis, sample size, trial duration, considerations for multicenter trials, stratifying trial recruitment according to the interstitium, and approaches to enrich recruitment, using examples of ongoing clinical trials.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research